Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.66
+0.74001.04%
Volume:719.14K
Turnover:51.64M
Market Cap:4.02B
PE:6.45
High:71.99
Open:70.93
Low:70.93
Close:70.92
52wk High:74.59
52wk Low:59.47
Shares:56.10M
Float Shares:56.10M
Volume Ratio:3.78
T/O Rate:1.28%
Dividend:0.81
Dividend Rate:1.13%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.44
PE(LYR):23.42

Loading ...

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30